EUVIMEDEUVIMED entdecken
Scoping Review

Behçet's Disease: Scoping Review with ☸️SAIMSARA

SAIMSARA Journal · 03.05.2026 · 1 (1)

DOI: 10.62487/saimsarac6b709d7 ↗

Kurz gefasst

Scoping Review in der Zeitschrift SAIMSARA Journal, online erschienen am 03.05.2026. Die Arbeit nennt 457 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To synthesize current evidence regarding the pathophysiology, clinical manifestations, diagnostic biomarkers, and therapeutic strategies for Behçet's disease based on a structured extraction of multi-center cohorts, case-control studies, and clinical trials. The review utilises 3695 original studies with 103639919 total participants (topic deduplicated ΣN). The mapped evidence supports Behçet's disease as a polygenic autoinflammatory vasculitis in which HLA-B*51–ERAP1 interactions, neutrophil hyperactivation with NETosis, and monocyte–macrophage dysregulation converge to drive multisystem injury, with the International Criteria for Behçet's Disease showing higher diagnostic sensitivity/coverage (81.0%–88.1%) than the older ISG criteria (43.3%–59.1%) and Paediatric Behçet's Disease criteria (37.3%). Across topics, anti-TNF therapy emerged as a recurrent signal of benefit in refractory ocular, vascular, neurologic, and intestinal disease, with vascular remission reported in approximately 89% of cases and adalimumab plus corticosteroids superior to ciclosporin for severe uveitis. Apremilast and emerging JAK inhibitors (baricitinib, upadacitinib) were associated with improvement in mucocutaneous and refractory intestinal/vascular phenotypes, while colchicine retained a role for mucocutaneous and joint manifestations. Diagnostic signals including common femoral vein wall thickness, OCT angiography, deep-learning endoscopy, and proteomic/metabolomic panels indicate a shift toward multimodal, non-invasive phenotyping, although venous thrombosis (~14% of patients), arterial aneurysms, and neuro-Behçet's disease continue to drive morbidity and mortality, particularly in young males. The map also highlights underrecognized burdens of fatigue, depression, sexual dysfunction, and monogenic Behçet-like mimics that warrant integrated psychosocial care and targeted genetic screening in early-onset or refractory presentations. Given the heterogeneity of small retrospective cohorts and the absence of pooled effect estimation, future work should prioritize multi-center randomized trials of JAK inhibitors, longitudinal microbiome studies, and standardized anticoagulation–immunosuppression protocols to resolve the most persistent uncertainties identified across this evidence map.

Zitieren

APA

(2026). Behçet's Disease: Scoping Review with ☸️SAIMSARA. SAIMSARA Journal, 1(1). https://doi.org/10.62487/saimsarac6b709d7

Vancouver

Behçet's Disease: Scoping Review with ☸️SAIMSARA. SAIMSARA Journal. 2026;1(1). doi:10.62487/saimsarac6b709d7

BibTeX
@article{euvimed2026,
  title = {Behçet's Disease: Scoping Review with ☸️SAIMSARA},
  journal = {SAIMSARA Journal},
  year = {2026},
  volume = {1},
  number = {1},
  doi = {10.62487/saimsarac6b709d7}
}
Kostenlos starten →